Results 41 to 50 of about 430,735 (248)

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

Comprehensive quality assessment for aphasia rehabilitation after stroke: protocol for a multicentre, mixed-methods study

BMJ Open
Introduction People with aphasia following stroke experience disproportionally poor outcomes, yet there is no comprehensive approach to measuring the quality of aphasia services.
Monique F Kilkenny, Joosup Kim, Dominique A Cadilhac, Deborah Hersh, Erin Godecke, David A Copland, Kathryn Mainstone, Penelope Mainstone, Sarah J Wallace, Miranda L Rose, Sam Harvey, Marissa Stone, Sally Zingelman, Muideen T Olaiya, Caterina Breitenstein, Kirstine Shrubsole, Robyn O’Halloran, Annie J Hill, Carolyn A Unsworth, Emily Brogan, Kylie J Short, Clare L Burns, Caroline Baker   +22 more
doaj   +1 more source

Pre‐analytical optimization of cell‐free DNA and extracellular vesicle‐derived DNA for mutation detection in liquid biopsies

Molecular Oncology, EarlyView.
Pre‐analytical handling critically determines liquid biopsy performance. This study defines practical best‐practice conditions for cell‐free DNA (cfDNA) and extracellular vesicle–derived DNA (evDNA), showing how processing time, storage conditions, tube type, and plasma input volume affect DNA integrity and mutation detection.
Jonas Dohmen, Lucrezia De Santis, Bret M. Stephens, Vincent Bernard, Jörg C. Kalff, Lara Braun, Phillipp Leyendecker, Johannes Röttgen, Daniel Weissinger, Anirban Maitra, Paola A. Guerrero, Alexander Semaan   +11 more
wiley   +1 more source

“Who are you going to call?:” Research ethics consultation directors’ perspectives on barriers and facilitators

Journal of Clinical and Translational Science
Introduction: Research ethics consultation services (RECS) provide important ethical guidance to various entities, including investigators and Institutional Review Boards.
Skye A. Miner, Jennifer B. McCormick, Holly A. Taylor   +2 more
doaj   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

EPIC-CP pilot trial study protocol: a multicentre, randomised controlled trial investigating the feasibility and acceptability of social prescribing for Australian children with cerebral palsy

BMJ Open
Introduction The social determinants of health contribute to poorer health outcomes for children with cerebral palsy (CP) and are barriers to families accessing health services.
Laurel Mimmo, , Karen Zwi, Susan Woolfenden, Georgina Chambers, Simon Paget, Raghu Lingam, Sarah Mcintyre, Sue Woolfenden, Valsamma Eapen, Hayley Smithers-Sheedy, Tanya Martin, Timothy Scott, Anne Masi, Iva Strnadová, Katarina Ostojic, Betty-Jean Dee-Price, Heather Burnett, Alison Berg, Michele Scarcella, Jack Calderan, Sheikh Azmatullah, Masyitah Mohamed, Mackenzie Woodbury, Alunya Wilkinson, Russell Dale, Isra Karem, Anne Olaso, Matthew van Hoek, Debbie van Hoek, Mariyam Cadiri, Delfina Diaz Rojas, Georgina Henry, Mick Scarcella, Shaini Shiva, Vesna Stojanovic, Debbie van Hoek, Matthew van Hoek, Joyce Vasquez, Janet Zacharko, Seaneen Wallace   +40 more
doaj   +1 more source

Lessons learned from implementing a responsive quality assessment of clinical ethics support

BMC Medical Ethics, 2019
Background Various forms of Clinical Ethics Support (CES) have been developed in health care organizations. Over the past years, increasing attention has been paid to the question of how to foster the quality of ethics support.
Eva M. Van Baarle, Marieke C. Potma, Maria E. C. van Hoek, Laura A. Hartman, Bert A. C. Molewijk, Jelle L. P. van Gurp   +5 more
doaj   +1 more source

Service intensity of community mental health outreach among people with untreated mental health problems in Japan: A retrospective cohort study

PCN Reports, 2023
Aim This study aimed to clarify the association between treatment status (untreated or treated) at the start of community mental health outreach services and service intensity.
Mai Iwanaga, Sosei Yamaguchi, Sayaka Sato, Kiyoaki Nakanishi, Erisa Nishiuchi, Michiyo Shimodaira, Yugan So, Kaori Usui, Chiyo Fujii   +8 more
doaj   +1 more source

Clinical Ethics Support Services: An Evolving Concept

, 2018
ABSTRACT Clinical ethics is a sub-domain of bioethics. Clinical ethics focuses on the ethical problems that arise as patients and physicians make decisions together. Such decisions are based primarily on medical indications and patient preferences. Clinical ethics identifies, analyses and attempts to resolve concrete problems that arise in patient care.
openaire   +2 more sources

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source